Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema.
This disease impairs patients' quality of life enormously. Pathological findings demonstrate …

Psoriasis is the result of uncontrolled keratinocyte proliferation, and its pathogenesis
involves the dysregulation of the immune system. The interplay among cytokines released …

This review discusses how oxidative stress (OS), an imbalance between oxidants and
antioxidants in favor of the oxidants, increased production of reactive oxygen species …

Psoriasis is an immune-mediated inflammatory disease, with a chronic relapsing-remitting
course, which affects 2–3% of the worldwide population. The progressive acquisitions of the …

Psoriasis is a systemic immune-mediated disease associated with an increased risk of
comorbidities, such as psoriatic arthritis, cardiovascular disease, metabolic syndrome …

Risankizumab is a humanized IgG monoclonal antibody inhibitor of IL23 and has been
recently approved by the EMA and the FDA for the treatment of moderate to severe plaque …

Severe psoriasis, a chronic inflammatory skin disease is increasingly being effectively
managed by targeted immunotherapy but long-term immunotherapy poses health risk and …

The approved biologics targeting interleukin (IL)-23 p19 for the treatment of moderate-to-
severe plaque psoriasis, including guselkumab, tildrakizumab, and risankizumab, have …

Psoriasis is a chronic multisystem inflammatory disease that affects~ 0.1–1.5% of the world
population. The classic cutaneous manifestation of psoriasis is scaly erythematous plaques …

Keywords: extra-articular manifestations; psoriasis; spondyloarthritis; uveitis EN extra-
articular manifestations psoriasis spondyloarthritis uveitis 183 186 4 01/31/23 20230201 …